Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial (2022)

First Author: Polizzotto M

Attributed to: Respiratory infections funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/s0140-6736(22)00101-5

PubMed Identifier: 35093205

Publication URI: http://europepmc.org/abstract/MED/35093205

Type: Journal Article/Review

Parent Publication: The Lancet

Issue: 10324

ISSN: 0140-6736